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Background/Objective: Cancer is the rapid, uncontrolled growth of cells. Cancer is the 
second leading cause of death in the United States. Chemotherapy is a major course of 
treatment used to cure and/or slow the growth of cancer. However, patients do not always 
choose to undergo chemotherapy. The objective of this review is to identify major factors 
that influence a patient’s decision to forego chemotherapy treatment.  
Method: This study was conducted by reviewing literature on the topic.  
Result: Progression of the disease, quality of life, religious factors, cultural values, 
financial ability, fertility, and physician recommendations were determined to be the main 
factors that influence a patient’s decision to forego chemotherapy.  
Conclusion: Patients consider a variety of factors when deciding to either begin 
chemotherapy or stop chemotherapy treatments. Patients and physicians may not share the 
same priorities for treatment options, but the patient will ultimately determine the decision. 
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Cancer has become a prevalent disease within the United States. Cancer is the 
second leading cause of death, and it is expected that cancer will surpass heart disease as 
the leading cause of death in the next few years (1). It is estimated that there will be 
1,658,370 new cases of cancer in 2015, equivalent to 4,500 new diagnoses per day (1). 
Researchers also estimate that 589,430 Americans will die of cancer in 2015 (1). Males 
have a 43% chance of developing invasive cancer over a lifetime, and women have a 38% 
chance (1). African-Americans have the highest incidence rates, whereas Asian/Pacific 
Islander-Americans have the lowest incidence rates (1). However, from 2004-2010, there 
was a 68% rate of survival for five years in all races surveyed (1). Death rates increased 
throughout most of the 20th century, but they have steadily declined since 1991 (1). As 
healthcare expands, scientific knowledge increases, and the general public is more 
educated about cancer, the death rate is expected to continue to decline (1).  
 There are multiple treatment options available for cancer patients. Chemotherapy is 
a treatment that uses drugs to kill cancer cells by stopping or slowing the growth of cells 
(2). Radiation therapy uses high doses of radiation to kill cancerous cells and shrink tumors 
(2). Radiation can be used to manage pain from tumors, cure cancer, or slow cancer growth 
(2). Surgery can also be used to remove cancer from the body (2). Other types of treatment 
include immunotherapy, stem cell transplant, and hormone therapy (2). The American 
Cancer Society stated that while some patients will undergo one type of treatment, most 
will have a combination of treatments (2). Often, patients will have surgery and then 
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follow up with a different form of treatment to eradicate the cancer cells left behind (2). 
Treatment plans will be individualized based on a variety of factors.  
 Chemotherapy can offer a host of benefits. Oncologists prescribe chemotherapy in 
order to prolong life, manage and prevent more symptoms, and improve over all quality of 
life (3). Chemotherapy can shrink tumors, relieving pain and pressure (5). Some patients 
may undergo chemo to reduce the tumor size before surgery or radiation (5). 
Chemotherapy may also be used after surgery or radiation. When used after surgery or 
radiation, chemotherapy can help to manage any cancerous cells left behind (5). 
Chemotherapy can also eradicate all cancerous cells from the body (5). However, it should 
be noted that cancer can return; thus, physicians are hesitant to say that the cancer is cured 
(5).  
With these potential benefits come several costs. A study that surveyed breast 
cancer patients reported that 22% of patients felt worse after chemotherapy (3). Only 26% 
of the patients surveyed reported feeling better after chemotherapy (3). Patients are also 
concerned with losing cognitive abilities, commonly called ‘chemo brain” (4). Nervous 
system distress occurs in a majority of patients undergoing chemotherapy (7). 
Chemotherapy can cause eating difficulties because it damages cells lining the mouth and 
intestines (2).  One of the most common side effects reported is nausea (6). In one study, 
nausea and vomiting were the most commonly observed side effects (7). Diarrhea also 
affected half of the participants (7). Fatigue and loss of appetite are also frequently 
reported (6). Feelings of sadness are often experienced, with the potential of leading to 
depression (6). In fact nearly 50% of cancer patients meet the criteria for a psychiatric 
diagnosis of depression (10). Hair loss has been demonstrated to be a common side effect 
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(7). Other risks include infertility, kidney problems, and anemia (2, 4).  
 A patient’s perspective is complex when making treatment decisions. Medical 
information can be difficult and overwhelming to attempt to understand (4). Patients are 
heavily influenced by their emotions and other experiences (8). Although most patients 
will defer to their doctor, they will be fielding various opinions from friends and family 
(9). Evidence suggests that patients will pursue the first treatment option they hear of, 
comparing other options to this first proposal (9). Moreover, it can be emotionally 
unsettling to deviate from the initial treatment plan (9). Age can also dictate patient 
perspective, as it encompasses experiences, culture, status quo, and individual priorities 
(10). 
 Physicians approach treatment decisions from a different context. It is natural that 
physicians will recommend treatments with which they have firsthand experience and 
know to be effective (8). Physicians will be limited in their experience with certain drugs 
and their respective outcomes (8). Physicians may be reluctant to try therapies with which 
they are unfamiliar versus options that they know well (8). Decisions made by physicians 
tend to involve less emotional factors than decisions made by patients, reducing cognitive 
biases (11). Physicians rely more on objective facts about treatments and associated 
benefits and risks (12). Quality of life may not weigh as heavily on a physician’s decision 
if a treatment is likely to extend life or greatly reduce the cancer (13). Therefore, physician 
recommendations are formed within this context and are often limited to the unique 
perspective of the physician (11).  
 It is with these considerations that patients will decide to forego chemotherapy 
treatment. There are many factors that patients consider for themselves. Each individual 
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views the significance of the benefits and risks of chemotherapy differently (4). Because 
chemotherapy is not the only treatment option, patients must weigh the costs associated 
with chemotherapy against other therapies. Considerations of quality of life, financial 
ability, personal beliefs, and the influence of the physician can affect the decision (4). It is 
important for both the patient and the physician to consider what would suit the patient 
best (4). Patients must also think ahead and consider issues such as fertility and potential 
health consequences (4).  
REVIEW OF FACTORS/DECISION 
Chemotherapy can affect a patient’s quality of life. The World Health Organization 
defines quality of life as, “An individual’s perception of life, values, objectives, standards, 
and interests, in the framework of culture.” (13) More specifically, health-related quality of 
life describes patient perception of his or her physical well being, psychological well-
being, daily activities, social life, and disease symptoms (14). While chemotherapy helps 
to alleviate symptoms of the cancer, chemotherapy itself introduces a new host of side 
effects (17); these side effects associated with chemotherapy can negatively affect quality 
of life (17).  
Quality of life encompasses many elements. The European Organization for 
Research and Treatment of Cancer produced a questionnaire referenced and used by many 
research teams to evaluate quality of life (14). The questionnaire evaluates physical, 
cognitive, emotional, role, and social functioning (14). Symptoms evaluated by the 
questionnaire include: fatigue, pain, dyspnea, insomnia, appetite loss, nausea, vomiting, 
constipation, diarrhea, and financial difficulties (14). Other symptoms such as hair loss, 
anemia, neuropathy, fever, and malaise are also included when evaluating quality of life 
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(16). Various other symptoms are evaluated with specificity to cancer types (14). It should 
be noted that quality of life does not differentiate the effects of cancer from the effects of 
chemotherapy (17).  
Figure 1: Key concepts that contribute to health-related quality of life in chemotherapy patients (50) 
The effects of chemotherapy on quality of life are a major cause of concern for 
cancer patients. The effects of chemotherapy cause almost fifty percent of patients to 
consider cessation of their chemotherapy treatment (16). Side effects associated with 
chemotherapy are well known to the general public, and thus they elicit fear from patients 
(16). Patients anticipate that they will suffer from chemotherapy (16). On average, patients 
report experiencing twenty common side effects, specifically thirteen physical and seven 
psychological (17).  
Physical Side Effects Psychological Side Effects 
Nausea Concern about effect on family 
Vomiting Depression 
Fatigue Anxiety 
Loss of taste/appetite Fear/dread of treatment 
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Hair loss Adverse effect on social life 
Top 5 Reported Physical and Psychological Side Effects 
Patients not only fear the physical side effects, but they dread how these effects will affect 
their social interactions and home life (15, 16). Patients also have great concern for how 
chemotherapy will affect their physical appearance as well as sexuality (15). 
Chemotherapy induced alopecia is one of the most paramount physical and 
psychological influences on quality of life. The most feared side effect of chemotherapy 
reported by women is hair loss (16). According to one study, hair loss is the most 
devastating effect of chemotherapy, particularly in women (14). Hair loss affects a patient 
not only physically, but also mentally, emotionally, and socially as well (14). Patients feel 
uncomfortable with their hair loss, and many will limit running errands or other activities 
in public as a result (22). Because alopecia is a commonly recognized side effect of 
chemotherapy, patients fear that they will be recognized and viewed as cancer patients 
(22). Some patients may be unable to properly cope with their chemotherapy if they suffer 
from alopecia (22). Alopecia exacts such a great toll on patients that some will forego 
chemotherapy in order to avoid hair loss (22).  
Difficulty in managing issues of quality of life may contribute to noncompliance. 
As a result of the onset of adverse side effects, patients may begin to be noncompliant with 
their treatment or cancer care in general (21). Noncompliance is generally caused by the 
inability to deal with severe symptoms and the interference of these symptoms with daily 
life (21). Symptoms such as chemotherapy-induced nausea and vomiting have caused 
patients to stop their chemotherapy regimens due to the severity of these side effects (19). 
Patients also become increasingly noncompliant with their clinic appointments as a result 
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of the difficulty of patients’ side effects (21). Patients may skip chemotherapy 
appointments to avoid receiving the treatments that decrease their quality of life (21). 
Statistically significant correlations were found between avoidance of clinic appointments 
and difficulty of dealing with hair loss, nausea, and loss of appetite (21).  
The direct financial costs of chemotherapy are another important factor for cancer 
patients. Direct costs are the financial compensations for services provided to the patient 
(20). These costs include the price of chemotherapy treatments, physician fees, and any 
other direct medical services (20). Monthly totals for chemotherapy alone can reach 
$34,000 (20). Although health insurance offsets some dues, most health insurance 
companies will require some out-of-pocket payments for chemotherapy regimens (20). 
Patients are responsible to pay approximately 20% of the cost of care out-of-pocket if they 
have insurance; by the end of treatment, this could amount to tens of thousands of dollars 
paid out-of-pocket (20). Insurance also may not cover prescription medication or other 
treatment-related expenses (26). Uninsured patients will bear the full costs of treatment 
(20). Because of the costs associated with chemotherapy, close to 2 million people 
diagnosed with cancer will not seek the medical treatment they need (20). Because cancer 
costs are highest at the beginning of treatment, many people may not even begin 
chemotherapy regimens (20).  
Indirect costs associated with chemotherapy are burdensome for cancer patients as 
well as loved ones. Financial losses incurred from lost time or productivity due to 
chemotherapy are indirect costs (20). Time spent at appointments can hinder a patient’s 
ability to continue to earn the same income he or she had before chemotherapy (20). Many 
patients have to travel to and from medical centers in another city or state, resulting in time 
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off work and potential decrease in pay (20). The side effects of chemotherapy may also 
limit the time that a patient is able to work as well as the efficiency of his or her work (20). 
Chemotherapy may hinder employment opportunities for patients, affecting health 
insurance coverage (26). This can exacerbate the issues of direct costs (20). Caregivers and 
loved ones also suffer from indirect costs (20). Limited employment opportunities, time 
away from work, and decrease in pay due to care for a patient also cost caregivers (20). 
Other unforeseen expenses include transportation arrangements, hotel stays, and childcare 
(26). These factors can affect the care and assistance that required by patients, thus 
reducing patients’ wills to receive and/or tolerate chemotherapy (20). 
Cultural values can prevent patients from seeking chemotherapy. The values and 
beliefs of cultures may dictate how patients view cancer and chemotherapy (24). Because 
of cultural stigmas surrounding cancer, patients often refuse to disclose their illness to 
members of their family or those who identify with their culture (24). As a result, patients 
are less likely to agree to undergo chemotherapy (24). Also, patients who are raised within 
certain cultures may have limited knowledge about chemotherapy, and thus refuse to 
consider it because of cultural stigmas (24). Some patients may view cancer as a 
punishment for their actions, and they may not seek treatment because of this (25). Latino, 
African, and Asian Americans are shown to be more fatalistic about the preventability of 
cancer as opposed to Caucasian Americans (27).  Some cultures that place great value on 
masculine identity may not be accepting of chemotherapy because it introduces weakness 
as well as physical changes to a man (25). Likewise, cultures with firmly defined roles for 
women may be unaccepting of chemotherapy because if women no longer function as the 
caretaker, she may feel shame (25). A woman’s body may also be held sacred by cultures, 
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and any violations of it are unacceptable; this could include physical examinations by a 
healthcare provider or effects of chemotherapy (25). One study found that 23% of percent 
of Caribbean women, 50% of Indian women, 52% of Pakistani, and 63% of Bangladeshi 
women believe that cancer is fate (27).  
Religious considerations may inhibit patients from choosing chemotherapy 
treatment. In one study of 257 participants, cancer patients were asked to complete a 
questionnaire that evaluated the importance of seven factors upon a patient’s treatment 
decision (23). Faith ranks second in the list, just behind physician recommendation (23). 
Some religions stringently adhere to the belief that there is something greater controlling 
all things, including cancer (27). Religions vary on attitudes about illness and disease. 
Catholics have reported to refuse chemotherapy because suffering enriches their faith 
experience (28). Catholics also refuse chemotherapy because Catholicism dictates that pain 
can only be relieved in ways that do not hasten death or harm the individual (28). Those 
who practice Judaism accept chemotherapy, but they may stop their treatments or decline 
starting chemotherapy if they believe their disease is terminal (28). Muslims may refuse 
chemotherapy, accepting their disease as a test of faith (28). Many sects and various 
religions exist that will have different values related to sickness and healthcare, affecting 
an individual’s decision to undergo chemotherapy. 
 Fertility and family planning can impact chemotherapy, causing patients to forego 
chemotherapy treatments. Fertility can be affected in both male and female patients (29). 
Because women are born with all of their reproductive oocytes, chemotherapy can 
compromise a woman’s ability to reproduce (29). Chemotherapy can cause premature 
menopause (29). Chemotherapy may hurt a fetus if a woman gets pregnant during 
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chemotherapy, when it begins, or soon after chemotherapy treatments (29). For these 
reasons, women are advised to take birth control and other precautions to avoid pregnancy 
during or up to six months after chemotherapy (29). Males can also suffer from infertility 
as a result of chemotherapy (30). High doses of alkylating agents can cause a decrease in 
sperm in nearly 90% of male patients (29). Males may have to wait several years to regain 
sperm production, if it can be regained at all (30). Male and female children potentially 
lose fertility due to chemotherapy, even if they have not reached puberty (30).  
Physicians may be reluctant to recommend chemotherapy for patients, dissuading 
patients from pursuing chemotherapy. The choice of treatment for patients is heavily 
influenced by the recommendations of the physician (31). Physicians consider a variety of 
factors, potentially from a different viewpoint than the patient (31). If a physician adopts 
the situation of the patient and would not go undergo chemotherapy his or herself, they are 
unlikely to recommend the treatment to a patient (31). Small gains made from 
chemotherapy that may sound enticing to a patient will not always be worth the costs from 
the perspective of the physician (31). Physicians also consider the ability of their patient to 
safely tolerate the chemo; if physicians believe chemotherapy would not be well tolerated, 
they may not pursue it (32). Oncologists are unlikely to recommend chemotherapy in 
patients of advanced age (32). Because patients with advanced age may have a progressed 
disease, a sense of a full and satisfying life, and a lower ability to tolerate harsh treatments, 
physicians are hesitant to move forward with chemotherapy (32). Physicians may also be 
less likely to pursue chemotherapy if they are unfamiliar with the disease and/or treatments 
(8). 
 16 
Chemotherapy does not always succeed. Oncologists typically look for a 20% 
response rate in chemotherapy regimens to classify a treatment as useful (36). Response 
rates are important because they give the physician a good indication of the potential for a 
new chemotherapy regimen to improve survival (34). The American Society of Clinical 
Oncology suggests that physicians do not administer chemotherapy if the treatment is very 
toxic or very costly and only produces marginal benefits (34). In patients with terminal 
lung, pancreatic, and colon cancer, studies have shown that survival rates are longer by 39 
days, 21 days, and 33 days respectively for patients who received hospice than patients 
who received chemotherapy (35).  
Patients often decide to forego chemotherapy when their cancer is unresponsive to 
chemotherapy. Cancer may progress despite chemotherapy (34). When standard 
chemotherapy regimens have not succeeded in halting the cancer, patients are unlikely to 
respond well to other regimens of chemotherapy (35). Guidelines established by the 
National Comprehensive Cancer Center Network suggest that after two chemotherapy 
regimens have failed, physicians should recommend hospice or palliative care rather than 
another line of chemotherapy (35). Additional chemotherapy administered to patients with 
unresponsive cancer will produce adverse effects and hospitalizations with no measureable 
benefit (35). Because of this, patients will not continue chemotherapy when their cancer is 
unresponsive.   
When curing the cancer is no longer an option, other short-term goals will become 
the priority. Although patients may still hope for a cure, they will change their treatment 
plan to meet other life or health goals (37). ). These goals could be a wedding,  a 
graduation, to create a will, or to spend their time with minimal adverse physical side 
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effects (37). When terminal cancer patients are asked what their end-of-life goals are, the 
top three responses include having meaningful experiences, connecting socially, and 
helping/supporting others; surprisingly, fighting cancer and being cured are ranked eight 
and eleventh, respectively (38). Because chemotherapy is likely to cause more hospital 
stays, increased doctor visits, and more prescriptions, chemotherapy may hinder patients 
from achieving their short-term goals (34, 37).  
 Although patients consider the advice of the physician, the decision to forego 
chemotherapy is ultimately in the power of the patient. It has not always been common for 
the patient to decide which treatment he or she will not undergo or if he or she will 
continue chemotherapy (8). With elevated risks of chemotherapy and the range of choices, 
ethics require that the patient be included in making treatment decisions (8). As patients 
become more educated about cancer and treatment options, they are more likely to assert 
their views and wills in the decision making process (39). In a study of advanced cancer 
patients, every patient reported that they wanted their physician to be involved in their 
treatment decision because of their knowledge and experience (39). However, only two 
patients wanted their physician to make treatment decisions without their input (39). The 
degree of patient involvement may vary with each doctor/patient relationship, but the 
American Society of Clinical Oncology strongly recommends that physicians actively 
involve patients in the decision making process so that patients may make the most 
educated decision (40). 
OTHER OPTIONS: 
Patients may pursue palliative care to assist in pain management throughout the 
course of their disease. the goal of palliative care is to provide a better quality of life for 
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patients and their loved ones by managing pain (44). A team of professionals, including 
physicians, nurses, social workers, chaplains, pharmacists, nutrionists, and ethicists work 
together to provide palliative care (41). Palliative care specialists will focus on treating 
physical side effects of chemotherapy as well as pain caused by the cancer itself (44). 
Specialists will also help with anxiety, depression, and/or confusion about any medical 
information (44). The American Society of Clinical Oncology suggests broader use of 
palliative care in order to manage quality of life for patients undergoing chemotherapy as 
well as those who do not undergo chemotherapy (42). Palliative care can be provided to 
patients prior to need of hospice, as palliative care can be provided at any stage of cancer, 
whereas hospice is specific to end-of-life care (41). 
When cancer has become terminal, patients may choose hospice care. The National 
Hospice and Palliative Care states, “At the center of hospice and palliative care is the belief 
that each of us has the right to die pain-free and with dignity, and that our loved ones will 
receive the necessary support to do so.” (41). As such, hospice is focused on end-of-life 
care to manage physical pain, control symptoms, and care for the psychological or spiritual 
needs of the patients and their families (42). The goal of hospice is to make patients and 
their families comfortable in the end of life, because hospice accepts that death is a natural 
part of life (42). On average, patients enter hospice care 55 days after the last dose of 
chemotherapy; this suggests cancer patients primarily use hospice when death seems 
imminent (43). Patients who receive a week or less of hospice care report the same quality 
of life as those who receive no hospice care (33). Longer levels of hospice care directly 
correlate to higher quality of life (33). Hospice care may become a more accessible option 
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for patients now as more health insurance companies are beginning to cover hospice care 
(37).  
  Patients and family members progress through several stages of acceptance of 
terminal cancer. Acceptance occurs both emotionally and cognitively (47). Elizabeth 
Kubler-Ross characterized a widely used model that describes how individuals progress to 
accept their death or the death of a loved one (45). Denial is the initial phase, followed by 
anger about cancer (45). Patients and family members move into a bargaining phase, in 
which they attempt to reverse the terminal cancer (45). When bargaining does not reverse 
the diagnosis, and the reality of terminal cancer sets in, patients and families may 
experience depression (45). If patients and loved ones progress through these stages, they 
will come to acceptance of terminal cancer (45). When families and patients have accepted 
cancer, they are able to make decisions regarding potential end of life care, wills, and 
specific health directives (48). Families will initially respond by unifying together to 
support the patient; however, family members may become increasingly stressed as the 
patient’s health declines because more caregiving is needed (46).  
 Patients who wish to continue treating their cancer may participate in clinical trials. 
Clinical trials are conducted when newly developed treatments or treatment methods are 
believed to improve patient care (51). New treatments must successfully progress through 
the four phases of clinical trials before the Food and Drug Administration can allow 
treatments on the market (52).  
Phase Purpose of Phase 
I Emphasizes safety; evaluation of side effects and how the body responds (if 
drug, how is it metabolized/excreted); 20-80 patient volunteers 
II Emphasizes effectiveness; does the treatment work in specific diseases? 
Participants are usually compared to a placebo group; hundreds of volunteers 
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III Further evaluation of safety and effectiveness amongst populations, with 
different doses, and in combination with other treatments; thousands of 
volunteers 
IV Monitoring the FDA-approved treatment for any side effects/outcomes not seen 
in clinical trials 
Figure 2: Phases of clinical trials as established by the FDA (52). 
Clinical trials are conducted with patients who volunteer to be part of the study (52). 
Patients may elect to participate in clinical trials in order to access the newest therapies for 
their cancer (53). Other patients may enroll in clinical trials as a service to research; patient 
participation helps researchers to learn more about potential treatments, even if the 
treatments are not successful in clinical trials (53). Because there is little known about the 
treatments used in clinical trials, patients do risk unknown side effects or unpredicted 
adverse outcomes (53).  
DISCUSSION: 
 Physicians, patients, and families view cancer care from their individual 
perspectives. Physicians approach treatment decisions from a more calculated perspective, 
because they draw upon their medical training (31). When presented with potential 
treatment options, physicians demand a higher success rate with lower risk than patients 
(11, 31). Patients are more willing to undergo treatments or therapies that promise little 
reward, even when they are fully aware of potential harm from the treatment (31). Families 
are often the most aggressive when making decisions about cancer care, because they do 
not want their loved one to stop treating the cancer (31). The limitations of the physician’s, 
the patient’s and the family’s perspectives can lead to a lack of understanding in the 
patient/physician relationship.  
Throughout the course of this research, I have concluded that there is an integral 
tension in the physician/patient relationship. Because patients and physicians approach the 
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cancer diagnosis and treatment plan(s) with differing perspectives, a fundamental tension is 
present within the patient/physician relationship. Physicians primarily consider objective 
facts by relying on their knowledge of cancer and potential treatments. Physicians present a 
calculated treatment plan with measurable and quantifiable goals. When chemotherapy no 
longer meets objective requirements, it is relatively easy for the physician to stop 
administering chemotherapy. On the contrary, patients process treatment decisions by 
considering not just medical facts, but they also drawn upon the influence of loved ones, 
emotions, and varying levels of education. Patients do not solely rely upon logic or 
rationale when they are battling cancer. Physicians may find the preferences or wishes of a 
patient to be irrational because the physician does not think like the patient. Patients, in 
turn, may find the physician to be insensitive to the concerns of the patient. Both the 
physician and the patient may voice their concerns and desires, but inherent differences in 
thought patterns could create barriers to productive communication. Tension in the 
physician/patient relationship can build if either or both parties see the other as an 
opposition to their views and does not affirm the validity of each person’s needs or 
opinions. Conversations altogether may be avoided because of tension in this relationship.  
There are valuable characteristics that optimize a physician’s patient care. It is 
important for the physician to recognize that the patient is likely to make decisions that are 
founded on subjective emotions. Despite the potential irrationalities of emotions, 
physicians should not discount the patient’s wishes or views. Patients respect the viewpoint 
of a physician, and many patients are looking for validation of the emotions they are 
experiencing. Physicians should clearly explain the status of a patient’s cancer, being 
aware that patients have varying educational backgrounds. It may also be important for a 
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physician to reiterate to the patient that physicians do not always have the answers. It 
should always be a priority of the physician to have open and honest communication, even 
if conversations may be difficult. Although there are many obligations of a physician, I 
believe that the greatest patient care begins with the physician. Physicians are entrusted 
with extensive responsibility, but if a physician is a good steward of this responsibility, 
there is opportunity for great patient care.  
In conclusion, I have learned imperative lessons that will prepare me for a career in 
medicine. It is imperative to maintain a health patient/physician relationship. I have learned 
the characteristics that optimize patient care, as well as characteristics that are detrimental 
to patient care. The power a physician holds when making treatment decisions should be 
recognized by the physician as an opportunity to protect the well being of a patient. I have 
also learned about the hardships inflicted by cancer on patients and their loved ones. 
Chemotherapy comes at a great cost, and no patient should feel forced to undergo 
chemotherapy treatment. Perhaps the greatest lesson I learned was that physicians possess 
great influence with patients and their families. Being a physician is not a responsibility to 
be taken lightly, and it demands special attention and care to ensure that patients receive 
the best treatment. I owe it to my future patients to utilize what I have learned and to 
maximize any opportunity to grow as a physician. I have been given a great privilege to be 
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